Ketamine Research: Hope for Resistant Depression Patients

New Research Reinforces Ketamine's Role in Hard-to-Treat Depression

A report published by The Jerusalem Post in late June 2026 spotlights growing scientific interest in ketamine as a treatment for depression that has not responded to conventional antidepressants — and, notably, for acute suicidal ideation. The piece draws on research characterizing ketamine not simply as a recreational substance but as a compound with a distinct and rapid mechanism of action that can produce meaningful symptom relief within hours to days, rather than the weeks typical of standard antidepressant therapy.

For the estimated 30 percent of people with major depressive disorder whose symptoms do not adequately respond to first- and second-line treatments, this body of evidence carries real clinical weight. Treatment-resistant depression (TRD) is associated with significant functional impairment, higher hospitalization rates, and elevated risk of self-harm. Effective options that work quickly have long been a priority for psychiatrists and their patients, and ketamine has moved steadily from emergency-use curiosity to an accepted tool in the treatment landscape over the past decade.

What the Science Says: Mechanism and Speed of Action

Conventional antidepressants — SSRIs, SNRIs, and tricyclics — work primarily by modulating serotonin, norepinephrine, or dopamine systems. Their effects typically build over four to eight weeks, which creates a significant treatment gap for patients in crisis. Ketamine operates through a different pathway: it acts as an antagonist at NMDA (N-methyl-D-aspartate) receptors in the brain's glutamate system, triggering a rapid cascade of neuroplastic changes that can lift depressive symptoms within hours of a single dose.

Research published across peer-reviewed psychiatry journals over the past several years has documented response rates in TRD patients that outpace placebo, with some studies reporting that 50 to 70 percent of TRD patients show meaningful short-term improvement. Effects on suicidal ideation appear particularly fast-acting, a property that has led some crisis-intervention and inpatient programs to incorporate ketamine protocols. The Jerusalem Post's coverage reflects a broader moment in which this evidence base is reaching a general audience, raising questions about who qualifies for treatment, what delivery formats are available, and how access is managed.

It is worth being precise about what the research does and does not establish. Studies consistently show rapid, short-term antidepressant and anti-suicidal effects. The durability of those effects — and the optimal dosing frequency needed to sustain them — remains an active area of investigation. Ketamine is not a permanent cure, and responsible clinical programs pair it with ongoing psychotherapy, psychiatry oversight, and clear re-evaluation schedules.

Where Ketamine Troches Fit in the Delivery Landscape

Most early research on ketamine for depression used intravenous (IV) infusions administered in a clinical setting over 40 minutes, typically in a series of six sessions. IV infusions allow precise dosing and rapid titration but require specialized infusion centers, are rarely covered by insurance for psychiatric indications, and typically cost $400 to $800 per session out of pocket.

Esketamine (Spravato), the FDA-approved intranasal formulation of a ketamine enantiomer, offers a more accessible supervised option, though it must be administered in a certified healthcare setting due to Risk Evaluation and Mitigation Strategy (REMS) requirements.

Compounded ketamine troches occupy a distinct position in this ecosystem. A troche is a small, slow-dissolving lozenge held between the cheek and gum, allowing ketamine to absorb through the oral mucosa and into the bloodstream — a route often described as sublingual or buccal delivery. Because troches are absorbed before reaching the digestive tract, they bypass the significant first-pass liver metabolism that would otherwise reduce bioavailability in oral tablet form. Compounding pharmacies produce these formulations under prescriber order, and many telehealth-based ketamine programs have made troches the cornerstone of at-home maintenance therapy.

For patients who have completed an initial infusion series or who are beginning a ketamine protocol under telepsychiatry guidance, troches can provide ongoing access to the therapy without requiring repeat clinic visits. They are typically dosed in the 100–400 mg range per session, taken in a calm, supervised home environment, and are timed to allow the dissociative effects — usually 45 to 90 minutes — to resolve before any driving or high-stakes activity. Patients using troches should understand that the bioavailability and onset timing differ from IV infusions, so direct dose-for-dose comparisons between formats are not straightforward.

What Broader Public Awareness Means for Patients and Providers

Articles like the one in The Jerusalem Post play an important role in shifting public perception of ketamine from a stigmatized club drug to a clinically validated treatment option. That shift can encourage patients who have cycled through multiple antidepressants without relief to ask their psychiatrists about ketamine, and it can prompt primary care providers to consider referrals earlier in the TRD journey.

At the same time, increased awareness brings legitimate questions about appropriate patient selection, provider credentials, and treatment quality. The rapid growth of telehealth ketamine programs since 2020 has expanded access meaningfully, but quality varies. Patients evaluating a ketamine program — whether for in-office infusions, nasal spray, or at-home troches — should look for programs that include a full psychiatric intake assessment, regular check-ins with a licensed prescriber, integration with psychotherapy when feasible, and clear protocols for what to do if symptoms worsen.

For troche patients specifically, the compounding route means the quality of the formulation depends on the pharmacy's standards. Working with an accredited compounding pharmacy — one that holds PCAB accreditation or operates under USP 795 and USP 800 guidelines — provides an additional layer of quality assurance. Your prescriber should be able to identify which pharmacy compounds their troche formulations and why they chose that partner.

The evolving research also signals that dosing and scheduling protocols for oral/buccal ketamine are still being refined. Some programs use twice-weekly troches; others space sessions further apart based on individual response. Tracking your mood, sleep, and anxiety symptoms between sessions — using a consistent scale like the PHQ-9 — gives your provider the data needed to adjust the plan over time rather than relying on subjective recall alone.

As the science matures, troches are likely to remain a central access point for patients who respond well to ketamine but cannot sustain frequent clinic visits. Understanding that troches represent a maintenance and access tool, not a replacement for the close medical oversight the research relies on, is the key frame for anyone considering or currently using this format.